MedicalMinute: Next Steps Following TNF Inhibitor Failure in IBD

Learn about current guideline recommendations for therapeutic drug monitoring of TNF-α inhibitor therapy and review key data informing second-line treatment decisions of moderate to severe UC and CD following TNF-α inhibitor failure.
Bruce E. Sands, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 337 KB
Released: May 24, 2021

Acknowledgements

Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Bristol-Myers Squibb

Related Content

Downloadable slides covering safety and efficacy data on new and emerging oral therapies for IBD, including S1PR modulators and JAK-STAT inhibitors.

Millie D. Long, MD, MPH Released: August 24, 2021

Interactive video from Dr. Millie Long and Clinical Care Options (CCO) on new and emerging oral IBD therapies

Millie D. Long, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: August 24, 2021 Expired: August 23, 2022

Expert commentary from Dr. Millie Long on the benefits of and barriers to patient participation in IBD clinical trials, from Clinical Care Options (CCO)

Millie D. Long, MD, MPH Released: August 17, 2021

Expert commentary from Dr. Millie Long on developing “activated” patients with IBD in your practice, from Clinical Care Options (CCO)

Millie D. Long, MD, MPH Released: July 13, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue